Norton Rose Fulbright Advises on Massive Monetisation Deal to Aid Cancer Treatment, Research
August 21, 2017
August 21, 2017
LONDON, Aug. 21 -- Norton Rose Fulbright, a law firm, issued the following news release:
Global law firm Norton Rose Fulbright has acted as the Australian legal advisers to the Walter and Eliza Hall Institute of Medical Research on the partial monetisation of a royalty due for sales of venetoclax, a new anti-cancer drug.
This significant US$325 million deal positions the Institute as a globally recognised innovator in medical research and comes after three decades of gr . . .
Global law firm Norton Rose Fulbright has acted as the Australian legal advisers to the Walter and Eliza Hall Institute of Medical Research on the partial monetisation of a royalty due for sales of venetoclax, a new anti-cancer drug.
This significant US$325 million deal positions the Institute as a globally recognised innovator in medical research and comes after three decades of gr . . .